Normal
ImmuPharma’s drug development and research

ImmuPharma’s low risk-strategy is to capitalize on pioneering research taking place primarily at Europe’s largest fundamental research institution, the Centre National de la Recherche Scientifique (National Center for Scientific Research) or CNRS. The CNRS was founded in 1939 and is a government-funded research organization, under the administrative authority of France's Ministry of Research and has over 30,000 employees and an annual budget of over €3 billion. The CNRS has received many prestigious awards and has produced 17 Nobel laureates and 11 Fields Medal award winners.

We have a significant collaborative research and development agreement with the CNRS, which grants ImmuPharma worldwide exclusive rights to exploit commercially certain discoveries. 

Our link with the CNRS allows ImmuPharma access to many scientists and doctors, keeping our costs low by avoiding the constant funding necessary for early stage research. 

Alongside our collaborations, we are using innovative technologies to develop a strong proprietary discovery pipeline and patented portfolio of potential new lead compounds.